Claims for Patent: 10,406,235

Summary for Patent: 10,406,235

Title:	Use of multi-arm polyethylene glycol modifier and application of multi-arm polyethylene glycol modifier in L-asparaginasum modification
Abstract:	Methods for use of a multi-arm polyethylene glycol (PEG) modifier in modification of asparaginase. The described multi-arm PEG modifier enhances the subunit interaction of a multimeric protein to maintain the multimeric protein in a polymerized form, thereby improving the stability of the multimeric protein, maintaining the bioactivity of the multimeric protein, and reducing the probability of exposure of the antigen binding site after depolymerization of the subunits, so as to reduce the immunogenicity.
Inventor(s):	Ma; Bruce Yong (Jiangsu, CN), Wang; Jun (Jiangsu, CN), Wu; Dinglong (Jiangsu, CN), Xu; Chunlin (Jiangsu, CN), Wang; Yaofang (Jiangsu, CN)
Assignee:	ZONHON BIOPHARMA INSTITUTE INC. (Changzhou, CN) GENSUN INSTITUTE OF BIOMEDICINE CO., LTD. (Changzhou, CN)
Application Number:	15/109,304
Patent Claims:	1. A multimeric protein modified with a multi-arm polyethylene glycol (PEG), the multi-arm polyethylene glycol comprising a chain of repeating units having from 2 to 16 activating groups that react with respective amino acid residues of subunits of the multimeric protein, wherein the activating groups enhance interaction between the subunits such that the multimeric protein modified with the multi-arm PEG has increased stability and reduced immunogenicity as compared with the multimeric protein when modified with a PEG comprising a chain having only 1 of the activating groups. 2. The multimeric protein modified with a multi-arm PEG according to claim 1, wherein the multi-arm PEG is selected from the group consisting of: ##STR00002## wherein n is an integer from 1 to 2000; k is 1 or 2; m is an integer from 2 to 16; p is an integer from 1 to 4; and the molecular weight of the multi-arm PEG is from 1 to 100 kDa. 3. The multimeric protein modified with a multi-arm PEG according to claim 2, wherein n is an integer from 2 to 500, k is 1, in is 4, and p is 2; and the molecular weight of the multi-arm PEG is from 1 to 40 kDa. 4. The multimeric protein modified with a multi-arm PEG according to claim 3, wherein the multi-arm PEG is an aldehyde or ester activated multi-arm PEG derivative, wherein the ester activated PEG derivative is selected from the group consisting of 4-arm PEG succinimidyl acetate, 4-arm PEG succinimidyl propionate and 4-arm PEG succinimidyl carbonate; and the aldehyde activated PEG derivative is selected from the group consisting of 4-arm PEG propionaldehyde, 4-arm PEG butyraldehyde, 4-arm PEG acetaldehyde and 4-arm PEG amylic aldehyde. 5. The multimeric protein modified with a multi-arm PEG according to claim 2, wherein the multimeric protein is selected from the group consisting of alkaline phosphatase, asparaginase and urease. 6. The multimeric protein modified with a multi-arm PEG according to claim 1, which is obtained by a method comprising the steps of: (1) mixing a protein to be modified, and a PEG modifier at a ratio, and subjecting them to modification in a buffer; (2) after the modification is completed, removing the PEG modifier in the modified product that is unreacted with the protein by ion exchange chromatography; and (3) purifying the modified product by gel filtration chromatography, to collect the modified product of interest; wherein the PEG modifier is selected from the group consisting of: ##STR00003## wherein n is an integer from 1 to 2000; k is 1 or 2; m is an integer from 2 to 16; p is an integer from 1 to 4; and the molecular weight of the multi-arm PEG is from 1 to 100 kDa. 7. The multimeric protein modified with a multi-arm PEG according to claim 1, which is an asparaginase modified with the multi-arm PEG. 8. A pharmaceutical composition comprising the asparaginase modified with a multi-arm PEG according to claim 7 and a pharmaceutically acceptable adjuvant, wherein the dosage form of the pharmaceutical composition is an injectable lyophilized powder. 9. The multimeric protein modified with a multi-arm PEG according, to claim 1, wherein the multi-arm PEG has the following structure: ##STR00004## wherein n is an integer from 1 to 2000; k is 1 or 2; m is, an integer from 2 to 16; and the molecular weight of the multi-arm PEG is from 1 to 100 kDa. 10. The multimeric protein modified with a multi-arm PEG according to claim 9, wherein the multimeric protein is alkaline phosphatase, asparaginase or urease, and the multi-arm PEG is selected from the group consisting of 4-arm PEG succinimidyl acetate, 4-arm PEG succinimidyl propionate and 4-arm PEG succinimidyl carbonate. 11. The multimeric protein modified with a multi-arm PEG according to claim 10, wherein the multimeric protein is asparaginase and the multi-arm PEG is 4-arm PEG succinimidyl acetate. 12. The multimeric protein modified with a multi-arm PEG according to claim 1, wherein the multi-arm PEG has the following structure: ##STR00005## wherein n is an integer from 1 to 2000; m is an integer from 2 to 16; p is an integer from 1 to 4; and the molecular weight of the multi-arm PEG is from 1 to 100 kDa. 13. The multimeric protein modified with a multi-arm PEG according to claim 12, wherein the multimeric protein is alkaline phosphatase, asparaginase or urease, and the multi-arm PEG is selected from the group consisting of 4-arm PEG propionaldehyde, 4-arm PEG butyraldehyde, 4-arm PEG acetaldehyde and 4-arm PEG amylic aldehyde. 14. The multimeric protein modified with a multi-arm PEG according to claim 13, wherein the multimeric protein is asparaginase and the multi-arm PEG is 4-arm PEG propionaldehyde. 15. A method for making the multimeric protein modified with a multi-arm polyethylene glycol (PEG) according to claim 1, comprising the steps of: (1) mixing a protein to be modified and a PEG modifier at a ratio, and subjecting them to modification in a buffer; (2) after the modification is completed, removing the PEG modifier in the modified product that is unreacted with the protein by ion exchange chromatography; and (3) purifying the modified product by gel filtration chromatography, to collect the modified product of claim 1; wherein the PEG modifier is selected from the group consisting of: ##STR00006## wherein n is an integer from 1 to 2000; k is 1 or 2; m is an integer from 2 to 16; p is an integer from 1 to 4; and the molecular weight of the multi-arm PEG is from 1 to 100 kDa. 16. The method according to claim 15, wherein n is an integer from 2 to 500, k is 1, m is 4, and p is 2; and the molecular weight of the multi-arm PEG is from 1 to 40 kDa. 17. The method according to claim 16, wherein the multi-arm PEG is an aldehyde or ester activated multi-arm PEG derivative, wherein the ester activated PEG derivative is selected from the group consisting of 4-arm PEG succinimidyl acetate, 4-arm PEG succinimidyl propionate and 4-arm PEG succinimidyl carbonate; and the aldehyde activated PEG derivative is selected from the group consisting of 4-arm PEG propionaldehyde, 4-arm PEG butyraldehyde, 4-arm PEG acetaldehyde and 4-arm PEG amylic aldehyde. 18. The method according to claim 17, wherein the multimeric protein is alkaline phosphatase, asparaginase or urease. 19. A method for treating a tumor comprising administering to a patient in need thereof a drug or pharmaceutical composition comprising the asparaginase modified with a multi-arm PEG according to claim 7.

Details for Patent 10,406,235

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2033-12-30